Lilly Company Profile

✉ Email this page to a colleague

LILLY has one hundred and five approved drugs.

There is one US patent protecting LILLY drugs.

There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-seven supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-003	Dec 24, 2003	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Lilly	KEFUROX	cefuroxime sodium	INJECTABLE;INTRAVENOUS	062592-001	Jan 10, 1986		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-001	Apr 9, 2007	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Lilly	NEBCIN	tobramycin sulfate	INJECTABLE;INJECTION	062008-004	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Lilly Res Labs	DYNABAC	dirithromycin	TABLET, DELAYED RELEASE;ORAL	050678-001	Jun 19, 1995		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Lilly	NEOTRIZINE	trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine)	TABLET;ORAL	006317-011	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Lilly	SANDRIL	reserpine	INJECTABLE;INJECTION	010012-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-004	Nov 26, 2002	5,658,590*PED	⤷ Sign Up
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	5,731,342	⤷ Sign Up
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	RE39049	⤷ Sign Up
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-001	Nov 21, 2003	7,182,958*PED	⤷ Sign Up
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	5,811,120	⤷ Sign Up
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-003	Dec 24, 2003	5,945,416	⤷ Sign Up
Lilly	DECABID	indecainide hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019693-001	Dec 29, 1989	4,389,393	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	For Injection	750 mg/vial	➤ Subscribe	2016-10-06
➤ Subscribe	Tablets	2.5 mg	➤ Subscribe	2008-10-14
➤ Subscribe	Delayed-release Capsules	20 mg, 30 mg and 60 mg	➤ Subscribe	2008-08-04
➤ Subscribe	Capsules	10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg	➤ Subscribe	2007-05-29
➤ Subscribe	Capsules	3 mg/25 mg	➤ Subscribe	2008-05-08
➤ Subscribe	For Injection	1g/vial	➤ Subscribe	2005-11-14
➤ Subscribe	For Injection	100 mg/vial	➤ Subscribe	2008-07-01
➤ Subscribe	For Injection	1000 mg/vial	➤ Subscribe	2012-06-27
➤ Subscribe	Injection	250 mcg/mL, 2.4 mL prefilled Pen	➤ Subscribe	2015-07-27
➤ Subscribe	Tablets	5 mg, 10 mg and 20 mg	➤ Subscribe	2007-11-21
➤ Subscribe	Delayed-release Capsules	40 mg	➤ Subscribe	2012-05-10
➤ Subscribe	Capsules	6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg	➤ Subscribe	2005-01-10
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2005-11-01
➤ Subscribe	For Injection	2 g/vial	➤ Subscribe	2007-08-24
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2008-02-04

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Mexico	PA06011230	⤷ Sign Up
South Korea	20060131946	⤷ Sign Up
Denmark	1732628	⤷ Sign Up
Portugal	1732628	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2005097240	⤷ Sign Up
Spain	2728788	⤷ Sign Up
Portugal	1732629	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0480717	98C0025	Belgium	⤷ Sign Up	PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0273658	2005C/001	Belgium	⤷ Sign Up	PRODUCT NAME: CHLORHYDRATE DE DULOXETINE; REGISTRATION NO/DATE: EU/1/04/280/001 20040811
1441735	SPC/GB08/020	United Kingdom	⤷ Sign Up	PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
2365988	CA 2018 00006	Denmark	⤷ Sign Up	PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721
2782584	301153	Netherlands	⤷ Sign Up	PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406
2957286	1990003-4	Sweden	⤷ Sign Up	PRODUCT NAME: PATRIOMER SORBITEX CALCIUM; REG. NO/DATE: EU/1/17/1179 20170721
2957286	2018C/047	Belgium	⤷ Sign Up	PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.